Latest Pharmaceuticals News

AFT Pharmaceuticals posted a 22% revenue jump to NZ$254.7 million and a 39% increase in operating profit to a record NZ$24.4 million for FY26, exceeding guidance. The company targets over NZ$300 million revenue for FY27, fueled by international expansion and a deepening R&D pipeline.

Argosy Property Limited reported a 3.3% rise in net property income to $120.8 million for FY26, underpinned by strong leasing, a $58.5 million revaluation gain, and progress towards a 50% green portfolio by 2031.

Island Pharmaceuticals has appointed Mark Herzog as Senior Global Health Security Advisor and secured roles in key Medical Countermeasures Coalition groups, boosting its US biodefence engagement ahead of pivotal Galidesivir Animal Rule studies.

Amplia Therapeutics has launched a Phase 2b trial testing a new daily dosing regimen of narmafotinib combined with chemotherapy in advanced pancreatic cancer, aiming to accelerate progress towards a pivotal Phase 3 study.

Whitefield Industrials reported a 5.6% drop in net profit to $21.1 million for FY2026 but maintained its fully franked dividend at 10.5 cents per share, while its portfolio outperformed the ASX200 Industrials benchmark over one and three years.

Algorae Pharmaceuticals has scaled its AI-driven drug synergy platform from one to 18 anchor drugs, generating over 9 million predictions and identifying thousands of promising combinations for cancer and other diseases.

ALS Limited reported a 25.8% jump in underlying net profit after tax to AUD 381.2 million for FY26, driven by strong commodity testing demand and margin expansion. The company raised its dividend and advanced major hub lab projects while navigating a post-year-end cyber incident.

Avecho Biotechnology has bolstered its cash reserves by $1.9 million through the exercise of listed options, positioning the company for a pivotal Phase III interim analysis readout for its insomnia treatment.

Bioxyne has locked in a two-year, $50 million exclusive supply agreement with German pharmaceutical distributor ADREXpharma, granting exclusive rights to its Dr Watson® brand in Germany and reinforcing its foothold in Europe’s largest medicinal cannabis market.

Acrux Limited has raised $1.6 million through a discounted share placement, attracting strong demand and offering attaching options to investors. The funds will support Phase III trials for female testosterone and a co-development deal with an international partner.

Bioxyne expands its LATAM footprint by securing the first international medicinal cannabis flower supply agreement in Costa Rica, with initial shipments valued over $500,000 planned before June 2026.

CSL Limited’s interim CEO Gordon Naylor reveals a downgraded FY26 outlook amid slower growth and announces substantial impairments tied to CSL Vifor assets. Leadership changes and transformation efforts aim to restore momentum.